News

Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more

Stocks have been off to a very bullish start in 2024, and investors seem increasingly optimistic about the overall state of the market and the global economy. Now, that's not to say there aren't

Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry

Image source: The Motley Fool.

MacroGenics (NASDAQ: MGNX)Q4 2023 Earnings CallMar 07, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Shares of Viking Therapeutics (NASDAQ: VKTX) were plunging 17.4% lower as of 11:52 a.m. ET on Thursday. This decline wasn't caused by an announcement by Viking. Instead, the sell-off appears to be

On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after

Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (NYSE: PFE) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's

The stock market has slowly started to come to its senses about telecom giant AT&T (NYSE: T). While the stock is still down significantly from its all-time high, shares have surged around 25% since

AT&T (NYSE: T) stock is going to hit a level it hasn't seen since June 2022. At least that's what analyst Peter Supino from Wolfe Research said when he upgraded shares of the telecommunications

The day after Intellia Therapeutics (NASDAQ: NTLA) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity analyst Whitney Ijem issued a new price target for the

Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (NYSE: LLY) is already giving Novo Nordisk (NYSE: NVO) a run for its money with the approval in the

Shares of telecommunications specialist AT&T (NYSE: T) popped on Tuesday, climbing as much as 3.3%. As of 1:30 p.m. ET, the stock was still up 2.6%.

The catalyst that sent the telecom stock higher

Super Micro Computer (NASDAQ: SMCI) stock is slipping in Tuesday's trading. The server-technology specialist's share price was down 5.5% as of 12:15 p.m. ET, according to data from S&P Global Market

The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NYSE:NVO), thanks to its type 2

It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting

No company has seen a greater benefit from the artificial intelligence boom than Nvidia (NASDAQ: NVDA). Training massive large-language models and running them requires gargantuan computing

The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite

On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process

Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.

Even the biggest and the best

With shares of Viking Therapeutics (NASDAQ: VKTX) flying 555% higher in the last three months, at least one financial analyst is saying that it can go even higher. On Feb. 28, Oppenheimer's Jay

Novavax (NASDAQ: NVAX) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported

Anti-obesity drugs rose in popularity last year, helping the leaders in this market -- notably Eli Lilly and Novo Nordisk -- crush the market. However, some medical device specialists got the wrong